Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 70

1.

Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer.

Costantini A, Corny J, Fallet V, Renet S, Friard S, Chouaid C, Duchemann B, Giroux-Leprieur E, Taillade L, Doucet L, Nguenang M, Jouveshomme S, Wislez M, Tredaniel J, Cadranel J.

ERJ Open Res. 2018 Apr 20;4(2). pii: 00120-2017. doi: 10.1183/23120541.00120-2017. eCollection 2018 Apr.

2.

Towards a RAS mutation status in a single day for patients with advanced colorectal cancers.

Barel F, Doucet L, Uguen A.

Dig Liver Dis. 2018 Mar 13. pii: S1590-8658(18)30221-4. doi: 10.1016/j.dld.2018.03.004. [Epub ahead of print] No abstract available.

PMID:
29622388
3.

The combination of targeted and systematic prostate biopsies is the best protocol for the detection of clinically significant prostate cancer.

Fourcade A, Payrard C, Tissot V, Perrouin-Verbe MA, Demany N, Serey-Effeil S, Callerot P, Coquet JB, Doucet L, Deruelle C, Joulin V, Nonent M, Fournier G, Valeri A.

Scand J Urol. 2018 Feb 20:1-6. doi: 10.1080/21681805.2018.1438509. [Epub ahead of print]

PMID:
29463177
4.

Development of a 'ready-to-use' tool that includes preventability, for the assessment of adverse drug events in oncology.

Hébert G, Netzer F, Kouakou SL, Lemare F, Minvielle E; IATRIGGER Working Group.

Int J Clin Pharm. 2018 Apr;40(2):376-385. doi: 10.1007/s11096-017-0542-3. Epub 2018 Feb 14.

PMID:
29446003
5.

Fatty acid profile in peri-prostatic adipose tissue and prostate cancer aggressiveness in African-Caribbean and Caucasian patients.

Figiel S, Pinault M, Domingo I, Guimaraes C, Guibon R, Besson P, Tavernier E, Blanchet P, Multigner L, Bruyère F, Haillot O, Mathieu R, Vincendeau S, Rioux-Leclercq N, Lebdai S, Azzouzi AR, Perrouin-Verbe MA, Fournier G, Doucet L, Rigaud J, Renaudin K, Mahéo K, Fromont G.

Eur J Cancer. 2018 Mar;91:107-115. doi: 10.1016/j.ejca.2017.12.017.

PMID:
29413967
6.

Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas.

Delahousse J, Verlingue L, Broutin S, Legoupil C, Touat M, Doucet L, Ammari S, Lacroix L, Ducreux M, Scoazec JY, Malka D, Paci A, Hollebecque A.

Eur J Cancer. 2018 Feb;90:83-91. doi: 10.1016/j.ejca.2017.11.024. Epub 2018 Jan 4.

PMID:
29274619
7.

Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.

Le Flahec G, Badic B, Guibourg B, Doucet L, Bail JP, Marcorelles P, Schick U, Uguen A.

Hum Pathol. 2018 Feb;72:135-143. doi: 10.1016/j.humpath.2017.09.019. Epub 2017 Dec 5.

PMID:
29208565
8.

Metabolic syndrome and low high-density lipoprotein cholesterol are associated with adverse pathological features in patients with prostate cancer treated by radical prostatectomy.

Lebdai S, Mathieu R, Leger J, Haillot O, Vincendeau S, Rioux-Leclercq N, Fournier G, Perrouin-Verbe MA, Doucet L, Azzouzi AR, Rigaud J, Renaudin K, Charles T, Bruyere F, Fromont G.

Urol Oncol. 2018 Feb;36(2):80.e17-80.e24. doi: 10.1016/j.urolonc.2017.09.026. Epub 2017 Nov 16.

PMID:
29153942
9.

Upfront immunohistochemistry improves specificity of Helicobacter pylori diagnosis. A French pathology laboratory point of view.

Ginestet F, Guibourg B, Doucet L, Théreaux J, Robaszkiewicz M, Marcorelles P, Uguen A.

Helicobacter. 2017 Oct;22(5). doi: 10.1111/hel.12424. Epub 2017 Aug 11.

PMID:
28799687
10.

MET Exon 14 Alterations and New Resistance Mutations to Tyrosine Kinase Inhibitors: Risk of Inadequate Detection with Current Amplicon-Based NGS Panels.

Poirot B, Doucet L, Benhenda S, Champ J, Meignin V, Lehmann-Che J.

J Thorac Oncol. 2017 Oct;12(10):1582-1587. doi: 10.1016/j.jtho.2017.07.026. Epub 2017 Aug 2.

PMID:
28779874
11.

Women Epidemiology Lung Cancer (WELCA) study: reproductive, hormonal, occupational risk factors and biobank.

Stücker I, Martin D, Neri M, Laurent-Puig P, Blons H, Antoine M, Guiochon-Mantel A, Brailly-Tabard S, Canonico M, Wislez M, Trédaniel J; WELCA study group.

BMC Public Health. 2017 Apr 17;17(1):324. doi: 10.1186/s12889-017-4191-1.

12.

Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents.

Grassi P, Doucet L, Giglione P, Grünwald V, Melichar B, Galli L, De Giorgi U, Sabbatini R, Ortega C, Santoni M, Bamias A, Verzoni E, Derosa L, Studentova H, Porcu L, De Braud F, Porta C, Procopio G.

Oncology. 2017;92(5):269-275. doi: 10.1159/000455970. Epub 2017 Feb 17.

PMID:
28208153
13.

Cystic Epithelial Tumors of the Prostate: One Case Supporting a Continuous Spectrum From Cystadenoma to Cystadenocarcinoma With Ductal Features.

Uguen A, Doucet L, Badic B, Perrouin-Verbe MA, Valeri A, Bail JP, Marcorelles P, Sibony M.

Am J Surg Pathol. 2016 Dec;40(12):1719-1721. No abstract available.

PMID:
27631516
14.

Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis.

Grassi P, Doucet L, Giglione P, Grünwald V, Melichar B, Galli L, De Giorgi U, Sabbatini R, Ortega C, Santoni M, Bamias A, Verzoni E, Derosa L, Studentova H, Pacifici M, Coppa J, Mazzaferro V, de Braud F, Porta C, Escudier B, Procopio G.

PLoS One. 2016 Apr 11;11(4):e0151662. doi: 10.1371/journal.pone.0151662. eCollection 2016.

15.

Prophylaxis of venous thromboembolism in cancer patients.

Frere C, Doucet L, Farge D.

Expert Rev Hematol. 2016 Jun;9(6):535-9. doi: 10.1586/17474086.2016.1172959. Epub 2016 May 3. Review.

PMID:
27031534
16.

NRASQ61R and BRAFV600E Mutation-specific Immunohistochemistry Is a Helpful Tool to Diagnose Metastatic Undifferentiated/Dedifferentiated Melanomas.

Uguen A, Sassolas B, Mondine P, Doucet L, Ginestet F, Benigni P, Costa S, De Braekeleer M, Marcorelles P.

Am J Surg Pathol. 2016 Jul;40(7):1004-5. doi: 10.1097/PAS.0000000000000647. No abstract available.

PMID:
26999502
17.

Three Rounds of External Quality Assessment in France to Evaluate the Performance of 28 Platforms for Multiparametric Molecular Testing in Metastatic Colorectal and Non-Small Cell Lung Cancer.

Dequeker EM, Keppens C, Egele C, Delen S, Lamy A, Lemoine A, Sabourin JC, Andrieu C, Ligtenberg M, Fetique D, Tops B, Descarpentries C, Blons H, Denoux Y, Aube C, Penault-Llorca F, Hofman P, Leroy K, Le Marechal C, Doucet L, Duranton-Tanneur V, Pedeutour F, Soubeyran I, Côté JF, Emile JF, Vignaud JM, Monhoven N, Haddad V, Laurent-Puig P, van Krieken H, Nowak F, Lonchamp E, Bellocq JP, Rouleau E.

J Mol Diagn. 2016 Mar;18(2):205-14. doi: 10.1016/j.jmoldx.2015.09.004. Epub 2016 Jan 2.

PMID:
26752307
18.

Effect of an Early Switch to Belatacept Among Calcineurin Inhibitor-Intolerant Graft Recipients of Kidneys From Extended-Criteria Donors.

Le Meur Y, Aulagnon F, Bertrand D, Heng AE, Lavaud S, Caillard S, Longuet H, Sberro-Soussan R, Doucet L, Grall A, Legendre C.

Am J Transplant. 2016 Jul;16(7):2181-6. doi: 10.1111/ajt.13698. Epub 2016 Mar 2.

19.

Remodelage de la signalisation calcique dans la tumeur prostatique : signature moléculaire de la récidive du cancer de prostate après chirurgie ?

Perrouin-Verbe M, Mignen O, Doucet L, Talagas M, Rosec S, Fournier G, Valeri A.

Prog Urol. 2015 Nov;25(13):839. doi: 10.1016/j.purol.2015.08.245. French. No abstract available.

PMID:
26544439
20.

Rôle des biopsies ciblées utilisant un système d'enregistrement 3D avec fusion élastique écho/IRM chez les hommes ayant une suspicion de cancer prostatique.

Fourcade A, Perrouin-Verbe M, Tissot V, Callerot P, Serey-Eiffel S, Cuvelier G, Coquet J, Doucet L, Delage F, Thoulouzan M, Fournier G, Valéri A.

Prog Urol. 2015 Nov;25(13):832. doi: 10.1016/j.purol.2015.08.230. French. No abstract available.

PMID:
26544424

Supplemental Content

Loading ...
Support Center